Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

33.21USD
10:55am EST
Change (% chg)

$-0.78 (-2.29%)
Prev Close
$34.35
Open
$33.58
Day's High
$33.58
Day's Low
$32.98
Volume
170,489
Avg. Vol
2,125,729
52-wk High
$38.15
52-wk Low
$32.29

RHHBY.PK

Chart for RHHBY.PK

About

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. The Company has two divisions: Pharmaceuticals and Diagnostics. It... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $233,532.09
Shares Outstanding(Mil.): 6,900.50
Dividend: 1.08
Yield (%): 3.20

Financials

  RHHBY.PK Industry Sector
P/E (TTM): 23.78 38.99 40.21
EPS (TTM): 1.43 -- --
ROI: 20.07 17.01 16.34
ROE: 48.00 17.53 17.27
Search Stocks

BRIEF-Roche says extends tender offer for Foundation Medicine

* Roche media release: Roche extends tender offer for Foundation Medicine Further company coverage: (Reporting By Zurich Slot)

02 Mar 2015

New Issue- Roche prices 1.0 bln euro 2025 bond

Lead Manager(s) BNP Paribas, Santander GBM & Unicredit

18 Feb 2015

UPDATE 1-Roche study shows Gazyva offers strong benefits as lymphoma drug

* Shares up 2.7 pct at 1057 GMT (Updates with shares, adds detail, analyst comment)

04 Feb 2015

BRIEF-FDA grants therapy designation for Genentech cancer treatment

* FDA grants breakthrough therapy designation for genentech's investigational cancer immunotherapy mpdl3280a (anti-pdl1) in non-small cell lung cancer

02 Feb 2015

Roche falls as dividend, earnings disappoint investors

ZURICH - Roche offered investors a lower-than-expected dividend payout on Wednesday and its earnings fell short of forecasts, sending shares in the Swiss drugmaker down more than two percent.

28 Jan 2015

UPDATE 2-Roche falls as dividend, earnings disappoint investors

* Shares fall more than 2 pct, underperform sector (Adds CEO, analyst comment, shares, details on franc, pipeline)

28 Jan 2015

Diagnostics, Tamiflu help Roche full-year sales beat poll

ZURICH - Swiss drugmaker Roche expects sales and profits to grow at a similar pace to last year, after a strong performance by its diagnostics unit and flu drug Tamiflu helped full-year sales beat expectations.

28 Jan 2015

RPT - INSIGHT-Safety concerns cloud early promise of powerful new cancer drugs

NEW YORK, Jan 26 - A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease.

26 Jan 2015

Safety concerns cloud early promise of powerful new cancer drugs

NEW YORK - A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease.

26 Jan 2015

INSIGHT-Safety concerns cloud early promise of powerful new cancer drugs

NEW YORK, Jan 26 - A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease.

26 Jan 2015

Competitors

Earnings vs. Estimates

Search Stocks